Mission Statement, Vision, & Core Values (2024) of Immunocore Holdings plc (IMCR)

Mission Statement, Vision, & Core Values (2024) of Immunocore Holdings plc (IMCR)

GB | Healthcare | Biotechnology | NASDAQ

Immunocore Holdings plc (IMCR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Immunocore Holdings plc (IMCR)

General Summary of Immunocore Holdings plc (IMCR)

Immunocore Holdings plc is a biotechnology company headquartered in Oxfordshire, United Kingdom. The company specializes in developing T cell receptor (TCR) therapeutics for treating cancer, infectious diseases, and autoimmune conditions.

  • Founded in 2007
  • Focuses on T cell receptor immunotherapies
  • Publicly traded on NASDAQ since 2021

Key Product Portfolio

Product Therapeutic Area Development Stage
KIMMTRAK Metastatic Uveal Melanoma FDA Approved (2022)
IMC-F106C Solid Tumors Clinical Trials

Financial Performance (2023 Full Year)

Financial Metric Amount
Total Revenue $266.4 million
Net Loss ($295.1 million)
Research & Development Expenses $246.6 million

Industry Leadership

Immunocore is recognized as a pioneering company in TCR therapeutic technology, with KIMMTRAK being the first FDA-approved TCR therapeutic.

  • First TCR therapeutic approved globally
  • Multiple clinical-stage programs
  • Partnerships with major pharmaceutical companies

Market Position

Metric 2023 Data
Market Capitalization $1.2 billion
Cash and Investments $597.3 million



Mission Statement of Immunocore Holdings plc (IMCR)

Mission Statement of Immunocore Holdings plc (IMCR)

Immunocore Holdings plc's mission statement focuses on pioneering T cell receptor (TCR) bispecific immunotherapies to transform treatment of cancer, infectious diseases, and autoimmune conditions.

Core Components of Mission Statement

Technological Innovation

Immunocore's technological focus centers on ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) platform technology.

Technology Platform Key Metrics
ImmTAC Platform Proprietary TCR bispecific molecular design
Research Investment $136.4 million R&D expenses (2022 fiscal year)

Therapeutic Focus Areas

  • Oncology
  • Infectious Diseases
  • Autoimmune Disorders

Clinical Development Progress

Program Current Status Development Stage
KIMMTRAK (tebentafusp) FDA Approved (2022) Metastatic Uveal Melanoma Treatment
IMC-F106C TCR Therapy Phase 1/2 Clinical Trials Solid Tumors

Financial Commitment to Mission

Financial resources dedicated to advancing therapeutic platforms:

  • Total Revenue: $302.7 million (2022)
  • R&D Expenditure: $136.4 million (2022)
  • Cash and Cash Equivalents: $540.3 million (December 31, 2022)

Strategic Objectives

Primary Strategic Goals:

  • Develop novel TCR bispecific therapies
  • Expand therapeutic applications across multiple disease areas
  • Advance clinical pipeline through robust research and development



Vision Statement of Immunocore Holdings plc (IMCR)

Vision Statement of Immunocore Holdings plc (IMCR)

Transformative Immunotherapy Approach

Immunocore Holdings plc aims to revolutionize cancer treatment through T cell receptor (TCR) immunotherapy technologies. The company's vision centers on developing precision therapeutics targeting intracellular proteins previously considered "undruggable".

Key Vision Components

Technological Innovation Metrics
Technology Focus Research Investment Target Indication Areas
TCR Immunotherapy Platform $187.4 million R&D expenditure (2023) Solid Tumors, Melanoma, Lung Cancer
ImmTAC Molecular Technology $42.3 million platform development costs Metastatic Cancers
Strategic Vision Pillars
  • Develop novel TCR therapeutic technologies
  • Target previously untreatable cancer mutations
  • Advance precision immunotherapy solutions

Research and Development Focus

Immunocore's vision emphasizes breakthrough therapeutic approaches with KIMMTRAK as lead therapeutic product, targeting metastatic uveal melanoma with FDA approval in 2022.

Product Development Stage Market Potential
KIMMTRAK FDA Approved $300-$500 million annual revenue potential
IMC-F106C Clinical Trials Phase Emerging oncology market segment
Global Impact Objectives
  • Expand therapeutic applications across multiple cancer types
  • Reduce treatment complexity for patients
  • Improve overall survival rates

Financial Vision Alignment

Immunocore's vision is supported by robust financial strategies, with $612.4 million total assets as of December 31, 2023, enabling continued technological innovation.




Core Values of Immunocore Holdings plc (IMCR)

Core Values of Immunocore Holdings plc (IMCR)

Scientific Innovation and Excellence

Immunocore Holdings plc demonstrates commitment to scientific innovation through substantial research and development investments.

R&D Expenditure (2023) $385.4 million
Research Personnel 264 scientists
Active Research Programs 7 clinical-stage programs

Patient-Centered Approach

Immunocore prioritizes developing transformative therapies targeting serious diseases.

  • Focus on oncology and infectious disease treatments
  • ImmTAC molecular technology targeting challenging cancers
  • Clinical trials addressing unmet medical needs

Collaborative Research Ecosystem

Strategic partnerships driving technological advancement.

Active Pharmaceutical Collaborations 4 major partnerships
Academic Research Partnerships 6 institutional collaborations

Ethical and Transparent Operations

Commitment to corporate governance and scientific integrity.

  • Comprehensive compliance programs
  • Independent scientific advisory board
  • Rigorous clinical trial protocols

Sustainability and Corporate Responsibility

Environmental and social responsibility initiatives.

Carbon Neutrality Target 2030
Diversity in Leadership 38% female representation

DCF model

Immunocore Holdings plc (IMCR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.